Tower Research Capital (TRC)’s Soleno Therapeutics SLNO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-4,900
| Closed | -$164K | – | 5602 |
|
|
2026
Q1 | $164K | Buy |
4,900
+4,569
| +1,380% | +$179K | ﹤0.01% | 1775 |
|
|
2025
Q4 | $15.3K | Sell |
331
-1,506
| -82% | -$82.6K | ﹤0.01% | 3291 |
|
|
2025
Q3 | $124K | Sell |
1,837
-1,279
| -41% | -$94.8K | ﹤0.01% | 1830 |
|
|
2025
Q2 | $261K | Buy |
3,116
+1,806
| +138% | +$135K | 0.01% | 1546 |
|
|
2025
Q1 | $93.6K | Sell |
1,310
-2,994
| -70% | -$146K | ﹤0.01% | 1808 |
|
|
2024
Q4 | $193K | Buy |
4,304
+3,832
| +812% | +$199K | ﹤0.01% | 1749 |
|
|
2024
Q3 | $23.8K | Sell |
472
-7,581
| -94% | -$363K | ﹤0.01% | 3142 |
|
|
2024
Q2 | $329K | Buy |
8,053
+4,981
| +162% | +$211K | 0.01% | 1681 |
|
|
2024
Q1 | $131K | Buy |
3,072
+2,592
| +540% | +$117K | ﹤0.01% | 1679 |
|
|
2023
Q4 | $19.3K | Sell |
480
-6,819
| -93% | -$194K | ﹤0.01% | 3672 |
|
|
2023
Q3 | $215K | Buy |
7,299
+6,568
| +898% | +$39.8K | 0.01% | 1384 |
|
|
2023
Q2 | $3.14K | Sell |
731
-2,083
| -74% | -$8.96K | ﹤0.01% | 5105 |
|
|
2023
Q1 | $6K | Sell |
2,814
-5,138
| -65% | -$11.5K | ﹤0.01% | 4875 |
|
|
2022
Q4 | $16K | Buy |
7,952
+7,090
| +823% | +$8.82K | ﹤0.01% | 3371 |
|
|
2022
Q3 | $1K | Buy |
862
+620
| +256% | +$1.51K | ﹤0.01% | 5835 |
|
|
2022
Q2 | $1K | Sell |
242
-254
| -51% | -$703 | ﹤0.01% | 5851 |
|
|
2022
Q1 | $2K | Buy |
496
+177
| +55% | +$917 | ﹤0.01% | 5595 |
|
|
2021
Q4 | $2K | Buy |
+319
| New | +$3.35K | ﹤0.01% | 5661 |
|
|
2021
Q3 | – | Sell |
-1,226
| Closed | -$21K | – | 6134 |
|
|
2021
Q2 | $21K | Sell |
1,226
-3,559
| -74% | -$60.1K | ﹤0.01% | 3853 |
|
|
2021
Q1 | $90K | Buy |
4,785
+4,329
| +949% | +$140K | ﹤0.01% | 2670 |
|
|
2020
Q4 | $13K | Sell |
456
-2,036
| -82% | -$58.8K | ﹤0.01% | 4161 |
|
|
2020
Q3 | $94K | Buy |
2,492
+2,091
| +521% | +$61.1K | ﹤0.01% | 3188 |
|
|
2020
Q2 | $13K | Buy |
+401
| New | +$17.4K | ﹤0.01% | 3907 |
|
|
2019
Q1 | – | Sell |
-156
| Closed | -$4K | – | 4234 |
|
|
2018
Q4 | $4K | Buy |
+156
| New | +$4.55K | ﹤0.01% | 3069 |
|
|
2016
Q2 | – | Sell |
-60
| Closed | -$5K | – | 4925 |
|
|
2016
Q1 | $5K | Sell |
60
-110
| -65% | -$10.8K | ﹤0.01% | 2729 |
|
|
2015
Q4 | $24K | Buy |
+170
| New | +$24.9K | ﹤0.01% | 1114 |
|
|
2015
Q3 | – | Sell |
-1
| Closed | – | – | 4685 |
|
|
2015
Q2 | $0 | Sell |
1
-2
| -67% | -$768 | ﹤0.01% | 4962 |
|
|
2015
Q1 | $1K | Sell |
3
-6
| -67% | -$1.78K | ﹤0.01% | 4125 |
|
|
2014
Q4 | $1K | Buy |
+9
| New | +$1.85K | ﹤0.01% | 3710 |
|
Tower Research Capital (TRC)'s SLNO Position: Q2 2026 in Review
Tower Research Capital (TRC) sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 4,900 shares — an estimated $164K sold.
Tower Research Capital (TRC) first reported a position in SLNO in Q4 2014 and held it in 29 quarters. The position peaked at $329K in Q2 2024. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.
- Tower Research Capital (TRC) reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
- Tower Research Capital (TRC) sold 4,900 Soleno Therapeutics shares in Q2 2026, an estimated $164K.
- Tower Research Capital (TRC) first reported a position in Soleno Therapeutics in Q4 2014 and held it in 29 quarters.
- Tower Research Capital (TRC)'s Soleno Therapeutics position peaked at $329K in Q2 2024.
- 0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.